Annexon, Inc

Arch Oncology, Inc in Brisbane is dedicated to the discovery and development of innovative antibody therapeutics for cancer patients. Their mission is to provide cutting-edge treatment options to improve the lives of individuals battling cancer. Generated from their website's infomation

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, CA, dedicated to advancing treatments for patients suffering from inflammatory and immunologic diseases. The company's innovative approach focuses on developing therapeutics that intelligently target key drivers of the immune system to transform treatment outcomes and enhance the quality of life for countless individuals. With a commitment to addressing conditions such as food allergies and other allergic diseases, RAPT Therapeutics is at the forefront of scientific research and development. The company aims to empower patients through cutting-edge therapies, exemplified by their long-acting anti-IgE antibody, RPT904, which is designed to make a significant difference in the lives of those affected. Generated from the website

Pionyr Immunotherapeutics, Inc., a biotechnology company based in South San Francisco, CA, was acquired by Ikena Oncology, Inc. in August 2023. Their innovative Myeloid Tuning programs aim to enhance the immune system's anti-tumor response by modifying the cellular infiltrate of the tumor microenvironment. With clinical programs targeting TREM2 and TREM1, Pionyr focuses on selectively depleting and reprogramming tumor-associated macrophages responsible for immunosuppression, demonstrating safety in Phase 1a b trials alone and in combination with pembrolizumab. Additionally, their IND-ready program, PY265 anti-MARCO, aims to activate the immune system in the tumor microenvironment. Pionyr Immunotherapeutics has made significant contributions to the field of immunotherapy, as evidenced by their posters, publications, and whitepapers. As part of Ikena Oncology, the company's business development team is open to discussions regarding licensing and partnerships for their pioneering programs. With a commitment to advancing cancer treatment, Pionyr Immunotherapeutics continues to make strides in developing novel therapies to combat tumors and improve patient outcomes.Generated from the website